GHRP-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. It was the first specific synthetic GH-releasing peptide developed by Cyril Bowers and colleagues at Tulane University in the late 1970s. It activates the ghrelin receptor (GHSR1a) on pituitary somatotrophs to trigger GH release, while also producing pronounced appetite stimulation through the same receptor system in hypothalamic feeding centers. The peptide established the foundation for the entire GHRP class and led to later development of GHRP-2, hexarelin, ipamorelin, and in the end the non-peptide oral analog MK-677.

The molecule was originally derived from chemical modification of met-enkephalin analogs. Bowers observed that enkephalin amide derivatives produced GH release in rat pituitary cultures despite acting through a receptor different from the GHRH receptor. This insight, that a separate receptor system existed for GH release, eventually led to the identification of the ghrelin receptor in 1996 (well before ghrelin itself was discovered as the endogenous ligand in 1999). GHRP-6 was thus the discovery tool for the entire ghrelin/GHSR1a signaling system.

The compound has a half-life of approximately 30 to 60 minutes when administered subcutaneously. The GH pulse peaks 15 to 30 minutes after injection and resolves within 2 to 3 hours. Multiple daily injections are typical in adult anabolic protocols.

The Published Clinical Evidence

The published clinical evidence for GHRP-6 is concentrated in pharmacology studies and small disease-focused trials.

Original Bowers studies. Multiple Phase 1 and pharmacology studies in the late 1980s and 1990s established the GH-releasing profile and the dose-response relationship for GHRP-6. These were the studies that confirmed the existence of a separate receptor system for GH release distinct from GHRH signaling.

Sleep studies. A 1995 study by Frieboes and colleagues in 7 healthy young males showed that repeated intravenous boluses of GHRP-6 during sleep increased serum GH, ACTH, and cortisol alongside increased time in stage 2 sleep. Later studies comparing oral, intranasal, and sublingual formulations did not produce the same sleep-EEG effects, suggesting the IV route is required for the central sleep modulation.

Acromegaly and Cushing's syndrome studies. GHRP-6 has been used in endocrine pharmacology to characterize hypothalamic-pituitary function in various endocrine disorders. The compound's ability to engage both the somatotrope and corticotrope axes makes it informative as a diagnostic probe.

Cardiac ischemia preclinical studies. Animal models of myocardial ischemia-reperfusion have documented cytoprotective effects of GHRP-6 (and other GHRPs, particularly hexarelin) on cardiac myocytes. The mechanism appears to involve direct ghrelin receptor signaling in cardiac tissue independent of the GH release.

Long-term therapeutic trials. Chronic GHRP-6 administration has not produced approved therapeutic indications. The trial dataset for chronic use is small, and the compound has not been pursued through Phase 3 development by any major pharmaceutical sponsor.

The structural problem with GHRP-6's evidence base is similar to GHRP-2's: the published literature is dominated by pharmacology studies rather than disease-focused efficacy programs. No Phase 3 trial in any specific therapeutic indication has been completed, which limits the regulatory positioning of the compound.

GHRP-6 binds the ghrelin receptor (GHSR1a) with the same mechanism as the rest of the GHRP family. The distinguishing feature is its strong appetite stimulation alongside the GH release.

GH release. Primary effect. The mechanism is GHSR1a activation on pituitary somatotrophs leading to GH pulse generation. GHRP-6's GH-releasing potency is moderate compared with GHRP-2 (which is approximately 5 to 10 times more potent) and hexarelin (similar potency).

Strong appetite stimulation. Distinguishing feature. GHRP-6 produces the most pronounced increase in appetite of any GHRP. The effect is mediated through GHSR1a activation in hypothalamic feeding centers (arcuate nucleus, paraventricular nucleus). The clinical manifestation is increased hunger, particularly within hours of administration, often described as ghrelin-like effects.

Cortisol and ACTH increase. Like other older GHRPs, GHRP-6 stimulates the HPA axis to some degree. The effect is comparable to GHRP-2 in magnitude.

Prolactin increase. Modest, similar to GHRP-2.

Cardiovascular effects. Multiple studies have documented GH-releasing peptides as cytoprotective agents in cardiac ischemia-reperfusion models. GHRP-6 specifically has been investigated in this context, though the cardiac protection effects are most prominent with hexarelin in the published animal literature.

The compound's clinical positioning has been defined by the appetite effect more than the GH potency. For users seeking GH release without strong hunger stimulation, ipamorelin (selective ghrelin receptor agonist without appetite effects) or MK-677 (oral) are generally preferred. For users in bulking phases who want both GH release and increased food intake, GHRP-6 has been the traditional choice.

Regulatory status

No FDA approval, no EMA approval, no marketing authorization in any country. GHRP-6 has not received regulatory clearance for any therapeutic or diagnostic indication. This is different from GHRP-2, which has the Japanese diagnostic approval (KP-102/Pralmorelin).

GHRP-6 was added to the FDA Category 2 bulks list under Section 503A in September 2023, prohibiting compounding pharmacy preparation. The compound is one of those scheduled for reconsideration at the PCAC meeting on July 23 and 24, 2026. Without an approved indication anywhere in the world and without a substantial published Phase 2/3 safety database, a Category 1 recommendation is unlikely.

GHRP-6 is on the WADA Prohibited List under section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Use in competitive sport is a doping violation in-competition and out-of-competition. Detection methods for GHRP-6 metabolites are established.

The compound continues to be sold by online research-chemical vendors as "for laboratory use only," with the standard quality control variability that applies to research-chemical peptides.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The safety profile of GHRP-6 is well characterized through pharmacology studies and adult research experience over four decades. The most consistent findings are:

Strong appetite stimulation. The most prominent effect. Users report substantial hunger increases within hours of administration. The effect is welcome for users in bulking phases but unwelcome for users seeking GH release without appetite changes. The hunger is described as ghrelin-like, with strong cravings for calorie-dense food.

Cortisol and ACTH increase. Similar magnitude to GHRP-2. Sustained cortisol increase with chronic dosing has metabolic and immune consequences that are undesirable.

Mild prolactin increase. May produce minor effects on libido or breast tissue.

Injection-site reactions. Common with subcutaneous administration. Generally mild and self-limited.

Headache and flushing. Reported at low rates.

Mild glucose increase. GH-induced insulin resistance is a class effect at higher cumulative doses.

Mild fluid retention. GH effect, dose-dependent.

The appetite effect is the dominant clinical signature of GHRP-6. For most adult anabolic users, this is the primary reason to choose GHRP-6 over more selective ghrelin receptor agonists like ipamorelin. For users where appetite control is a goal (such as during cutting phases), GHRP-6 is a poor choice and would be replaced by ipamorelin or a GHRH analog.

The GHRP family includes several compounds with different selectivity profiles and clinical positions.

GHRP-6 vs GHRP-2. GHRP-2 has approximately 5 to 10 times higher GH-releasing potency. GHRP-6 has stronger appetite stimulation. The two have comparable cortisol, ACTH, and prolactin effects.

GHRP-6 vs Hexarelin. Hexarelin has stronger cardiac protective effects in animal models. The GH-releasing potency is comparable. Hexarelin has been more studied in cardiovascular research; GHRP-6 has been more studied in endocrinology.

GHRP-6 vs Ipamorelin. Ipamorelin retains GH-releasing potency while substantially reducing the cortisol, ACTH, prolactin, and appetite effects. This selectivity makes ipamorelin generally preferred for adult anabolic use where appetite control matters.

GHRP-6 vs MK-677. MK-677 is the oral non-peptide ghrelin receptor agonist. It also stimulates appetite (similar to GHRP-6) but provides 24-hour GH/IGF-1 increase from once-daily oral dosing rather than multiple daily injections. MK-677 has a much larger Phase 2 evidence base.

GHRP-6 vs ghrelin itself. GHRP-6 is a synthetic mimetic of ghrelin signaling. Ghrelin itself is rarely used therapeutically because of rapid degradation and short half-life. GHRP-6 was the first stable synthetic agonist of the ghrelin receptor (developed before ghrelin was discovered).

For practical adult use, the choice between GHRP-6 and other GH secretagogues depends primarily on whether appetite stimulation is desired. For bulking with concurrent GH support, GHRP-6 has the historical positioning. For GH support without appetite changes, ipamorelin or GHRH analogs are preferred.